Senator Stefanik brought Senate Bill 39 (pharmaceutical access for rare diseases) to the floor, describing the measure as eliminating certain preauthorization requirements for rare‑disease treatments. The sponsor and supporters emphasized that when time matters clinical outcomes improve and that patients with rare conditions should not be delayed by administrative preauthorization processes.

On the floor, the bill’s proponents described the federal benchmark that defines a rare disease as affecting fewer than 200,000 people in the United States and cited examples from testimony, including necrotizing myopathy and hemophilia B. Senator Tobiason (floor speaker in support) recounted personal familiarity with rare‑disease impacts and urged the body to adopt the change to reduce delay and improve patient access to treatment.

The sponsor moved final passage on the floor. The transcript records the motion to pass the bill as amended, but a floor roll‑call tally was not recorded in the provided transcript excerpt. Floor debate was limited and supportive; no detailed fiscal note or vote count appears in the available floor excerpt.